Me-toos close in on Bioverativ's next-gen hemophilia portfolio

29 September 2017

Before Bioverativ (Nasdaq: BIVV) found a way to extend the half life of recombinant factor therapies, hemophilia patients required a transfusion as often as every other day, resulting in higher bleed frequency and associated morbidity.

The new approach, in which a fragment of the immunoglobulin protein Fc is fused to clotting factor, is significantly more stable once injected into the body. This makes the treatment last for days or even weeks.

Alprolix (coagulation factor recombinant) for hemophilia B and Eloctate (antihemophilic factor recombinant) for hemophilia A gained US FDA approval in 2014. The products are commercialized in Europe by Swedish Orphan Biovitrum (STO: SOBI).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK